Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00290771 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
A Phase 2 study, sponsored by Novartis.
- Terminated
- Registry status
- Phase 2
- Development phase
- 231
- Enrollment target
NCT00290771 is a Phase 2 study that was terminated before completion, run by Novartis. The registered enrollment target is 231 participants.
The verdict
NCT00290771, a Phase 2 study, was terminated before completion, sponsored by Novartis.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 231 participants
- Enrollment target
Study Summary
This was an investigational study to assess the objective overall response (OOR) rate (complete response \[CR\] + partial response \[PR\]) of imatinib mesylate and hydroxyurea (hydroxycarbamide) combination therapy in patients with recurrent glioblastoma multiforme (brain tumors). This study also evaluated the duration of tumor response (as per MacDonald criteria), clinical benefit, progression-free survival rate at 6 and 12 months, and the survival rate at 12 and 24 months.
Interventions
- DRUG Imatinib tablets
- DRUG Hydroxyurea capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2006-02 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00290771
The ClinicalTrials.gov registry entry for NCT00290771 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Imatinib tablets is the first listed.
NCT00290771 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00290771 about?
NCT00290771 is a clinical study titled "Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)". This was an investigational study to assess the objective overall response (OOR) rate (complete response \[CR\] + partial response \[PR\]) of imatinib mesylate and hydroxyurea (hydroxycarbamide) combination therapy in patients with recurrent glioblastoma multiforme (brain tumors). This study also ev...
What is the current status of trial NCT00290771?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 231 participants. The study started on 2006-02. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00290771?
The interventions under investigation include: Imatinib tablets (DRUG), Hydroxyurea capsules (DRUG).
Who is sponsoring clinical trial NCT00290771?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.